VENTURE: VK2735 Phase 2 trial (NCT06068946)
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 13-week Study of VK2735 for Weight Management in Subjects Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition
Registry record checked
At a glance
- Phase
- Phase 2
- Status
- Completed
- Enrolment
- 176
- actual
- Start
- 31 Aug 2023 (actual)
- Primary completion
- 27 Feb 2024 (actual)
- Sponsor
- Viking Therapeutics, Inc.
Design
Arms and doses
| Arm | Type | Interventions | Description |
|---|---|---|---|
| VK2735 (Placebo) | Placebo comparator | Biological: Placebo | Placebo |
| VK2735 (Dose #1) | Experimental | Biological: VK2735 | VK2735 is a peptide GLP-1 and GIP dual agonist |
| VK2735 (Dose #2) | Experimental | Biological: VK2735 | VK2735 is a peptide GLP-1 and GIP dual agonist |
| VK2735 (Dose #3) | Experimental | Biological: VK2735 | VK2735 is a peptide GLP-1 and GIP dual agonist |
| VK2735 (Dose #4) | Experimental | Biological: VK2735 | VK2735 is a peptide GLP-1 and GIP dual agonist |
Endpoints
Primary endpoint
| Measure | Time frame |
|---|---|
| Percent (relative) change from baseline to Week 13 in body weight | 13 weeks |
Endpoints
Key secondary endpoints
The first secondary outcomes listed on the registry record.
| Measure | Time frame |
|---|---|
| Proportion of Subjects losing ≥5% and ≥10% of baseline weight at Week 13 | 13 weeks |
Eligibility
Who could enrol
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- Not stated
Results
Results
No results posted on ClinicalTrials.gov as of 2 Oct 2026.
Sources
- 1A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 13-week Study of VK2735 for Weight Management in Subjects Who Are Obese, or Overweight With at Least One Weight-related Comorbid ConditionClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
Found an error? Report a correction.